Bayer wins FDA approval for first Factor XIa blood thinner

· Health · United States

Bayer received U.S. FDA approval for Sunharbo, the first Factor XIa inhibitor cleared in the United States, according to BioPharma Dive and STAT. The drug is designed to prevent blood clots and reduce stroke recurrence without increasing bleeding risk, a long-sought goal for anticoagulant developers. Factor XIa inhibitors have been watched as a potential step forward in stroke prevention because existing blood thinners carry bleeding hazards. The approval gives Bayer an early position in a new drug class that rivals are also pursuing.

Why it matters：The first Factor XIa approval sets a regulatory benchmark for a closely watched anticoagulant class and could reshape stroke-prevention competition.

Key points

  • Sunharbo is the first Factor XIa inhibitor approved in the U.S.
  • The class aims to prevent clots without raising bleeding risk.

Sources (original reporting)

More stories from this day